Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/569

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/001982MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION
WO 26.01.2023
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Appl.No PCT/EP2022/070541 Applicant UNIVERSITÄT BASEL Inventor FLOHR, Alexander
The present invention relates to ligands specifically presented by MR1 molecules to MR1-specific T cells. These ligands are derivatives or analogues of nucleic acid forming bases, particularly ribonucleoside and deoxyribonucleoside adducts occurring in eukaryotic cells under certain conditions. The invention further relates to pharmaceutical preparations and methods for use of such ligands in treatment and research. The invention further relates to pharmaceutical preparations provided with the aim of modulating presentation of MR1 ligands in clinical situations where such modulated presentation of MR1 ligands is of clinical benefit.
2.WO/2023/004038METHODS FOR PREDICTING AND/OR MONITORING CANCER TREATMENT RESPONSE USING CHANGES IN CIRCULATING CANCER ASSOCIATED MACROPHAGE-LIKE CELLS (CAMLS)
WO 26.01.2023
Int.Class G01N 33/483
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
483Physical analysis of biological material
Appl.No PCT/US2022/037874 Applicant CREATV MICROTECH INC. Inventor ADAMS, Daniel L.
Means for predicting treatment response in a subject having cancer are disclosed, where the predictions are based comparing the number and size of circulating cancer associated macrophage-like cells (CAMLs) and circulating tumor cells (CTCs) found in biological samples at baseline and after induction of therapy, such as blood, from the subject.
3.WO/2023/002892METHOD AND DEVICE FOR DETECTING BIOMOLECULE
WO 26.01.2023
Int.Class G01N 27/02
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
27Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
02by investigating impedance
Appl.No PCT/JP2022/027516 Applicant THE UNIVERSITY OF TOKYO Inventor SAKATA Toshiya
The present disclosure provides a method that is for detecting a biomolecule, the method comprising: providing an electrode 101, and an aptamer 102 that is disposed in the vicinity of the electrode 101, that specifically binds to the target biomolecule, and that has an electric charge; introducing a cation mediator 113 having an electric charge opposite to the electric charge of the aptamer 102 into the electrode 101, at which the aptamer 102 is located; bringing a solution containing the target biomolecule into contact with the aptamer 102, and causing the aptamer 102 to bind to the target biomolecule; and measuring an electrical signal produced at the electrode 101 by the cation mediator 113.
4.WO/2023/004335SELECTION OF VIRAL-SPECIFIC CYTOTOXIC T-CELL LINES FOR THE MANAGEMENT OF VIRAL INFECTIONS
WO 26.01.2023
Int.Class G16H 20/10
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
20ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
10relating to drugs or medications, e.g. for ensuring correct administration to patients
Appl.No PCT/US2022/073913 Applicant BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor REZVANI, Katy
Embodiments of the disclosure concern systems, methods, and compositions related to identification of a suitable cell therapy for an individual in need thereof. A cell line is selected from a plurality of cell lines for suitability for an individual based on an algorithm and cell identification number that includes values for HLA matching and the frequency of reactive CD4 and CD8 cytotoxic T lymphocytes as measured by interferon-γ and IL-2. Particular parameters for HLA matching and reactive frequencies are utilized to calculate points towards the cell identification number, and the cell line with the highest cell identification number may be utilized.
5.WO/2023/003334RAPID KIT FOR DIAGNOSIS OF CORONAVIRUS-NEUTRALIZING ANTIBODY
WO 26.01.2023
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/KR2022/010554 Applicant MICO BIOMED CO., LTD. Inventor KIM, Sung Woo
The present application pertains to a rapid kit for diagnosis of coronavirus-neutralizing antibody and a method for detection of a neutralizing antibody by using same, wherein the kit comprises: a first sample pad for accommodating a sample; a first condensation pad including a conjugate a coronavirus spike protein or a fragment thereof and gold particles, the coronavirus spike protein or the fragment binding specifically to a neutralizing antibody contained in the sample introduced into the first sample pad; a second condensation pad including an ACE2 protein binding specifically to the spike protein or the fragment thereof; a membrane provided in contact with one end of the second condensation pad and having an antibody fixed thereat, the antibody binding specifically to the ACE2 protein or a fragment thereof; and an absorption pad provided in contact with an end of the membrane and absorbing the sample after completion of the reaction.
6.WO/2023/003679SINGLE DOMAIN ANTIBODIES THAT BIND AND NEUTRALIZE VENEZUELAN EQUINE ENCEPHALITIS VIRUS
WO 26.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2022/035483 Applicant THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY Inventor LIU, Jinny Lin
Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Venezuelan equine encephalitis virus (VEEV).
7.WO/2023/001736ENGINEERED ANTI-SARS COV-2 IgG3 ANTIBODIES
WO 26.01.2023
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/EP2022/070005 Applicant UNIVERSITÄT FÜR BODENKULTUR WIEN Inventor STEINKELLNER, Herta
The present invention refers to a recombinant anti-SARS CoV-2 antibody with enhanced viral neutralization potency comprising an lgG3 constant and hinge region with one or more engineered glycans. The invention refers also to a nucleic acid encoding the anti-SARS CoV-2 antibody, plant cells expressing the anti-SARS CoV-2 antibodies, a method for production of anti-SARS CoV-2 antibody, and a pharmaceutical composition comprising anti-SARS CoV-2 antibody. The invention also refers to the use of an anti-SARS CoV-2 antibody for detecting SARS CoV-2 in a sample, the use for the manufacture of a medicament, and the use for treating or preventing diseases associated with coronavirus infections.
8.WO/2023/002996METHOD FOR DETECTING VIRUS IN SPECIMEN, AND VIRUS DETECTION APPARATUS
WO 26.01.2023
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
Appl.No PCT/JP2022/028103 Applicant NANOTIS CORPORATION Inventor MIYAZAKI, Jinsei
The present invention relates to a method for detecting a virus in a specimen, the method comprising: a step for preparing a test solution containing the specimen, a surfactant and a fluorescently labeled anti-nucleocapsid protein antibody; a step for bringing the test solution into contact with a microelectrode and then applying a voltage to concentrate the fluorescently labeled anti-nucleocapsid protein antibody that bounds to a nucleocapsid protein of the virus in the specimen in a region in the vicinity of the microelectrode; and a step for detecting the presence of the virus in the specimen by the fluorescence observation. In the method, the nucleocapsid protein forms a complex in conjunction with a nucleic acid.
9.102021013981ELETRODOS BASEADOS EM ÓXIDOS DE GRAFENO REDUZIDO PARA APLICAÇÕES EM DETECÇÃO VIRAL
BR 24.01.2023
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 102021013981 Applicant FUNDAÇÃO UNIVERSIDADE FEDERAL DO ABC - UFABC Inventor ANA MELVA CHAMPI FARFÁN
ELETRODOS BASEADOS EM ÓXIDOS DE GRAFENO REDUZIDO PARA APLICAÇÕES EM DETECÇÃO VIRAL. A presente invenção refere-se a eletrodos baseados em óxidos de grafeno reduzido para aplicações em detecção viral. Especificamente, a presente invenção é utilizada em métodos de detecção de cargas em uma solução, tomando por base mudanças elétricas ocorridas durante reações químicas, sendo que o dito eletrodo é revestido com uma camada de óxido de grafeno reduzido.
10.102021013930DIAGNÓSTICO IMUNOLÓGICO DA COVID-19
BR 24.01.2023
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No 102021013930 Applicant UNIVERSIDADE FEDERAL DE PELOTAS Inventor ANA VITÓRIA COSTA
DIAGNÓSTICO IMUNOLÓGICO DA COVID-19. A presente invenção enquadra-se na área de Biotecnologia e refere-se a um ensaio imunoabsorvente (ELISA) que detecta e mensura anticorpos IgG, IgM ou IgA anti-SARSCov-2, agente etiológico da COVID-19, para fins de diagnóstico clínico, estudos epidemiológicos, monitoramento vacinal e pesquisa/desenvolvimento tecnológico. Diferentemente da maioria dos testes sorológicos comerciais que utiliza uma proteína de SARS-Cov-2 como antígeno (S ou N), a presente invenção descreve a produção e uso em imunodiagnóstico de uma quimera recombinante composta por regiões imunodominantes das duas principais proteínas antigênicas de SARS-Cov-2, conferindo elevada sensibilidade e especificidade ao teste. Esta quimera antigênica é produzida em alta quantidade por Escherichia coli e apresenta elevada estabilidade. A otimização de todas as etapas e insumos usados no ELISA com um painel de 1000 soros nacionais possibilitou o desenvolvimento de um teste de elevada acurácia e reprodutibilidade.